Immunotoxin

The immunotoxin is composed of two main parts. The first is a single-chain antibody fragment (scFv) directed to Pbs2l, a surface membrane protein of P. berghei ookinetes. This fragment is linked to the second part, a lytic peptide, Shiva-1. Shiva-1 is a synthetic peptide with an amino acid sequence similar, in terms of length (38 amino acids, charge distribution as well as hydrophobicity, to Cecropin B which is an antibacterial peptide. The purpose of the immunotoxin is to specifically target and lyse the parasite.

Previous experiments conducted show that feeding mosquitoes with recombinant E.Coli that expressed this immunotoxin induced a significantly lower oocyst density. [1]

However E. Coli is not a natural symbiote of the mosquito. We would like to contribute to the fight against malaria by engineering Asaia in order to express the immunotoxin in the mosquito's intestinal tract, and run experiments to see if it significantly reduces the number of oocysts.

The sequence of the immunotoxin was taken from our reference paper [1], and the codons were optimized for E.Coli. The codon optimized sequence can be found here.

The "P-proteins"

P25 and P28 are a class of important proteins expressed on the membrane of different type of Plasmodium; we call this ensemble of evolutionary conserved proteins the P-proteins. They are mainly mainly expressed on the mosquito-stage parasite (ookinete). The ookinete has been intensively studied by scientists, looking for an ideal transmission-blocking vaccine target.

Why the P-preoteins?

Plasmodium proteins P25 and P28 are important for the protection of P. falciparum. In fact, they are very abundant on the ookinete surface and this coating prevents the action of hard proteolytic environment from the gut and reduces the exposition of the ookinete to it. Other functions of the P-proteins are involved with gametes fusion as well as ookinete entry into midgut epithelial cells. The process of penetration through the epithelium is essential for the ookinete maturation and propagation and experiments have shown that double-knockout of these proteins significantly reduces the migration of parasites across the midgut. An interesting observation is that parasites lacking either P25 or P28 are transmitted efficiently by mosquitoes. It is rather the double knockout of these proteins that compromises greatly the parasites propagation by the mosquito. In fact, it has been shown that the binding of specific antibodies to these surface proteins was fatal to more than 99% of the parasites by inhibiting their interactions [2]. This indicates that these two proteins have partially redundant functions. Experiments have shown that even when the ookinete could traverse the midgut epithelium these proteins are important for further development of the ookinete into oocysts [3].

The team decided to design Asaia to express a soluble form of these two P-proteins. It may seem contra-intuitive to provide more of these proteins (by expression in Asaia) that are essential for survival, migration, and development of the parasite. However, our hypothesis is based on the fact that these proteins over-expressed in a soluble form would compete with the parasite surface protein and prevent the interaction necessary to its transmission. Because the functions of P25 and P28 are redundant, both proteins need to be inhibited or outcompeted to efficiently block the malaria transmission.

Structural information about P-proteins

The two P-proteins were conserved throughout evolution. They have a C-terminal glycosylphosphatidylinositol that anchors the proteins on the plasmodium membrane so that it is accessible from the extracellular side.

Sizes of the genes: The two genes does not contain introns so that we can directly perform a PCR on the genomic DNA of the plasmodium. The length of P25 and P28 genes are 654 and 657 bp respectively.

An interesting feature of the X-ray crystal structure of the Pvs25 : the four EGF-like domains form a compact triangular prism. These prisms are arranged on layers of sheets in the crystal. P. falciparum P25 (Pfs25) likely assume a similar structure. These structures may play a role of protection of the parasite, cysteins play an important role to maintain this structure by making 11 and 10 disulfide bonds in the P25 and P28 protein respectively.

Figure 1. Sheets of Pvs25 (Plasmodium vivax) in the crystal structure

In order to find the protein, we attached a His tag to the P-proteins when we designed the primers to extract the proteins from the Plasmodium gDNA. We attached it to the C-terminus. The reason for that is that the C-terminus is involved in the attachment of the protein to the plasmodium outer membrane and thus should not e involved on the P-protein – P-protein and P-protein – Receptor interactions. This idea is supported by experiments with transmission-blocking antibodies. Indeed wee can see on the figure that the epitop of the transmission-blocking antibody is far away from the C-terminus. So we think that the addition of the His-tag does not compromise the functionalities of the proteins.

Figure 2. Heavy chain (dark blue) of the transmission-blocking antibody binding the Pvs25 protein

References:

• [http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T29-42JHDJD-9&_user=10&_coverDate=03%2F31%2F2001&_rdoc=1&_fmt=high&_orig=search&_origin=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=5f4b78b08a1846e241faaed33bc76cb3&searchtype=a 1. Shigeto Yoshida, Bacteria expressing single-chain immunotoxin inhibit malaria parasite development in mosquitoes, Molecular and Biochemical Parasitology (2001)]
• [http://www.nature.com/emboj/journal/v20/n15/full/7593895a.html 2. Ana M. Tomas, Gabriele Margos, Robert E. Sinden, P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions, The EMBO Journal (2001)]
• [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1951121/?tool=pubmed 3. Ajay K. Saxena, Yimin Wu, and David N. Garboczi, Plasmodium P25 and P28 Surface Proteins: Potential Transmission-Blocking Vaccines, Eukaryot Cell (2007)]